VAR2 PHARMACEUTICALS ApS
CVR 34621942 · Private limited company (ApS) · Active · Low risk
VAR2 PHARMACEUTICALS ApS is a Private limited company (ApS), founded on , based in Frederiksberg. The company is registered in the industry forskning og eksperimentel udvikling inden for naturvidenskab og teknik. Our model estimates a bankruptcy risk of 0.1% over the next 12 months, which is 0.0 times the average for Danish companies. 14 annual reports have been published. The latest annual report (31 Dec 2025) shows equity of DKK 82.0m and a net result of DKK -19.7m. CEO: Ali El-Salanti, Mads Daugaard.
Bankruptcy risk for VAR2 PHARMACEUTICALS ApS
0.0 × the average (1.41%) · higher risk than 27% of active Danish companies
Increases the risk
Reduces the risk
The factors show how often companies with the same characteristic went bankrupt compared with the average (“lift”). The risk is a statistical estimate from a model trained on 141,000+ Danish bankruptcies (AUC 0.93) – not a credit rating. Read about the method.
Company details
- CVR number
- 34621942
- Status
- Active
- Company type
- Private limited company (ApS)
- Founded
- (14 years)
- Address
- c/o Symbion Fuglebakken, Nordre Fasanvej 215
2000 Frederiksberg - Municipality
- Frederiksberg
- Industry
- Forskning og eksperimentel udvikling inden for naturvidenskab og teknik (721000)
Bankruptcies in the industry: Anden forskning og eksperimentel udvikling inden for naturvidenskab og teknik - Share capital
- DKK 118k
- Employees
- 11 (2018)
- Auditor
- PKF Munkebo Eriksen Funch, Statsautoriseret Revisionsaktieselskab
- Audit opted out
- No
Warning signs
| Annual reports filed late | 0 of 14 |
| Missing annual report | No |
| Negative equity | No |
| Equity ratio | 95.7% |
| Current ratio | 2,360% |
| Moves (last 2 years) | 0 |
| CEO changes in total | 3 |
| CEO's previous bankruptcies | 0 |
| Other companies at the address | 111 |
| Going-concern uncertainty | No |
Financials and key figures
| Financial year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Gross profit | DKK -21.7m | DKK -22.7m | DKK -22.3m |
| Net profit | DKK -19.7m | DKK -21.0m | DKK -19.1m |
| Equity | DKK 82.0m | DKK 64.5m | DKK 48.3m |
| Total assets | DKK 85.7m | DKK 66.7m | DKK 59.3m |
| Cash | DKK 48.0m | DKK 41.3m | – |
| Short-term debt | DKK 3.4m | DKK 1.9m | – |
| Avg. employees | 7 | 8 | – |
Latest annual report: Reporting class B · auditor's statement: Revisionspåtegning · PKF Munkebo Eriksen Funch, Statsautoriseret Revisionsaktieselskab.
Filed annual reports
| Reporting period | Published | Days after period end | |
|---|---|---|---|
| 1 Jan 2025 – 31 Dec 2025 | 159 | ||
| 1 Jan 2024 – 31 Dec 2024 | 147 | ||
| 1 Jan 2023 – 31 Dec 2023 | 148 | ||
| 1 Jan 2022 – 31 Dec 2022 | 153 | ||
| 1 Jan 2021 – 31 Dec 2021 | 110 | ||
| 1 Jan 2020 – 31 Dec 2020 | 179 | ||
| 1 Jan 2019 – 31 Dec 2019 | 125 | ||
| 1 Jan 2018 – 31 Dec 2018 | 143 | ||
| 1 Jan 2017 – 31 Dec 2017 | 151 | ||
| 1 Jan 2016 – 31 Dec 2016 | 153 | ||
| 1 Jan 2015 – 31 Dec 2015 | 153 | ||
| 1 Jan 2014 – 31 Dec 2014 | 152 | ||
| 1 Jan 2013 – 31 Dec 2013 | 152 | ||
| 1 Jun 2012 – 31 Dec 2012 | 147 |
The annual report must reach the Danish Business Authority no later than 5 months after the end of the financial year. We mark reports published more than 6 months after as “late”.
Management, owners and auditor
| Role | Name | From | To |
|---|---|---|---|
| CEO | Ali El-Salanti | Current | |
| CEO | Mads Daugaard | Current | |
| CEO | Thor Grundtvig Theander | ||
| CEO | Ulf Andreas Linderoth Norlin | ||
| Board | Thor Grundtvig Theander | Current | |
| Board | Ali El-Salanti | Current | |
| Board | Mads Daugaard | Current | |
| Board | Peter Schröcksnadel | Current | |
| Board | Poul Henrik Bredahl Sørensen | Current | |
| Board | Josef Rainer | Current | |
| Board | Tanja Rainer | Current | |
| Board | Silviya Stoykova | Current | |
| Board | Mai-Britt Zocca | ||
| Owner (5%) | Københavns Universitet | Current | |
| Owner (90%) | ONCOMAL ApS | Current | |
| Auditor | PKF Munkebo Eriksen Funch, Statsautoriseret Revisionsaktieselskab | Current | |
| Founder | ONCOMAL ApS | Current | |
| Founder | Københavns Universitet | Current |
The CEOs' other companies
Ali El-Salanti – 4 other companies
- AdaptVac ApS Active
- NextGen Vaccines Holding ApS Active
- ONCOMAL ApS Active
- VarCT Diagnostics ApS Active
Mads Daugaard – 4 other companies
- Daugaard-Peterslund Invest ApS Active
- FarmLaser ApS Active
- ONCOMAL ApS Active
- VarCT Diagnostics ApS Active
Thor Grundtvig Theander – 4 other companies
- ACIL ApS Fusioneret
- FEVACIL ApS Active
- ONCOMAL ApS Active
- VarCT Diagnostics ApS Active
Address history (1 moves)
| c/o Symbion Fuglebakken, Nordre Fasanvej 215, 2000 Frederiksberg | |
| c/o Cobis A/S, Ole Maaløes Vej 3, 2200 København N |
Employees per year
Other companies at the same address
- Nordetect ApS Bankrupt
- ACESION PHARMA ApS Active
- AdaptVac ApS Active
- Adcendo ApS Active
- Akylox Therapeutics ApS Active
- Antraka ApS Opløst
- Augustine Therapeutics Denmark ApS Active
- Autocert ApS Active
- Avancert ApS Active
- B4C ApS Active
- BOOST Pharma ApS Active
- Baekmark IP Consult ApS Active
- Betula Capital ApS Active
- BioPhenyx ApS Active
- Biobridge Partners ApS Active
- Biotinia ApS Active
- CMCAssist ApS Active
- CMCGreenhouse ApS Active
- CMCHoldings ApS Active
- CaMaRa ApS Active
- Catalyst Vaccination A/S Active
- Chris Cording Jønsson Holding ApS Active
- DARERL ApS Active
- DFY ApS Active
- DeltaBot ApS Active
Similar companies in Frederiksberg
- Koblano Therapeutics ApS Frederiksberg
- Eygo Bio ApS Frederiksberg
- LumenAR ApS Frederiksberg
- IDTA ApS Frederiksberg
- Valicentra ApS Frederiksberg
- Silvics ApS Frederiksberg
- InLife Research ApS Frederiksberg
- NordicRWE Denmark ApS Frederiksberg C
- CaMaRa ApS Frederiksberg
- Hvidberg Compliance Management Aps Frederiksberg
- Vibraint ApS Frederiksberg
- Augustine Therapeutics Denmark ApS Frederiksberg
Questions and answers about VAR2 PHARMACEUTICALS ApS
Has VAR2 PHARMACEUTICALS ApS gone bankrupt?
No, VAR2 PHARMACEUTICALS ApS is not registered as bankrupt in the CVR register. Its status is: active.
What is the bankruptcy risk of VAR2 PHARMACEUTICALS ApS?
Our model estimates a bankruptcy risk of 0.1% over the next 12 months (low risk), which is 0.0 times the average for Danish companies.
Who is the CEO of VAR2 PHARMACEUTICALS ApS?
Ali El-Salanti, Mads Daugaard are the CEOs of VAR2 PHARMACEUTICALS ApS.
Who is the auditor of VAR2 PHARMACEUTICALS ApS?
VAR2 PHARMACEUTICALS ApS most recently used PKF Munkebo Eriksen Funch, Statsautoriseret Revisionsaktieselskab.
When was VAR2 PHARMACEUTICALS ApS founded?
VAR2 PHARMACEUTICALS ApS was founded on 1 June 2012.
What is the equity of VAR2 PHARMACEUTICALS ApS?
Equity was DKK 82.0m according to the annual report for the period ending 31 December 2025.
Source: the CVR register and annual reports published by the Danish Business Authority. The information is updated continuously.